Evidence of Clinical Activity in a Phase I Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies

被引：0

作者：

Flinn, Ian W. ^{[1
]}

Byrd, John C. ^{[2
]}

Furman, Richard R. ^{[3
]}

Brown, Jennifer R. ^{[4
]}

Benson, Don M. ^{[5
]}

Coutre, Steven E. ^{[6
]}

Kahl, Brad S. ^{[7
]}

Smith, B. Douglas ^{[8
]}

Wagner-Johnston, Nina D. ^{[9
]}

Spurgeon, Stephen E. ^{[10
]}

Giese, Neill A. ^{[11
]}

Yu, Albert S. ^{[12
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Ohio State Univ, Coll Med, Columbus, OH 43210 USA

[3] Weill Cornell Med Coll, New York, NY USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Ohio State Univ, Div Hematol Oncol, Columbus, OH 43210 USA

[6] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[7] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Hematol Oncol Sect, Madison, WI USA

[8] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[9] Washington Univ, Sch Med, St Louis, MO USA

[10] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[11] Calistoga Pharmaceut Inc, Seattle, WA USA

[12] Calistoga Pharmaceut, Seattle, WA USA

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：380 / 380

页数：1

共 50 条

[21] CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies
Lannutti, Brian J.
Meadows, Sarah A.
Kashishian, Adam
Steiner, Bart
May, Sarah
Johnson, Amy J.
Ulrich, Roger G.
Yu, Albert
Gallatin, Michael W.
Byrd, John C.
Puri, Kamal D.
Giese, Neill A.
BLOOD, 2008, 112 (11) : 12 - 12
[22] DEMONSTRATION OF PHARMACODYNAMIC TARGET INHIBITION AND CHEMOKINE MODULATION IN PATIENTS WITH CLL FOLLOWING TREATMENT WITH CAL-101, A SELECTIVE INHIBITOR OF THE P110 DELTA ISOFORM OF PI3K
Lannutti, J.
Meadows, A.
Kashishian, A.
Steiner, B.
Webb, K.
Peterman, S.
Yu, A.
Giese, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 45 - 46
[23] A phase I/II study of the selective phosphatidylinositol 3-kinase -delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL)
Furman, Richard R.
Barrientos, Jacqueline Claudia
Sharman, Jeff Porter
De Vos, Sven
Leonard, John
Coutre, Steven E.
Schreeder, Marshall T.
Wagner-Johnston, Nina D.
Boyd, Thomas E.
Fowler, Nathan Hale
Flinn, Ian W.
Boccia, Ralph V.
Holes, Leanne
Lannutti, Brian Joseph
Johnson, Dave
Jahn, Thomas Michael
Miller, Langdon L.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[24] A phase I study of a selective PI3Kδ inhibitor YY-20394 in patients with relapsed or refractory B-cell malignancies.
Qiu, Lugui
Qi, Junyuan
Song, Yuqin
Jiang, Bo
Tu, Meifeng
Ping, Lingyan
Li, Zengjun
Zhu, Jun
Xu, Yuanyuan
Bao, Hanying
Xu, Zusheng
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[25] A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Sharman, Jeff
de Vos, Sven
Leonard, John P.
Furman, Richard R.
Coutre, Steven E.
Flinn, Ian W.
Schreeder, Marshall T.
Barrientos, Jaqueline C.
Wagner-Johnston, Nina D.
Boyd, Thomas
Fowler, Nathan H.
Holes, Leanne
Lannutti, Brian
Johnson, David
Jahn, Thomas M.
Miller, Langdon L.
BLOOD, 2011, 118 (21) : 779 - 780
[26] Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study
Coutre, Steven E.
Leonard, John P.
Furman, Richard R.
Barrientos, Jacqueline C.
de Vos, Sven
Flinn, Ian W.
Schreeder, Marshall T.
Wagner-Johnston, Nina D.
Sharman, Jeff
Boyd, Thomas E.
Fowler, Nathan H.
Holes, Leanne M.
Lannutti, Brian J.
Johnson, Dave M.
Miller, Langdon L.
Jahn, Thomas M.
BLOOD, 2012, 120 (21)
[27] A phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed/refractory B-cell lymphoma
Shah, N. K.
Rule, S.
Salles, G.
Karlin, L.
Morschhauser, F.
Terriou, L.
Dyer, M.
Hutchinson, C.
Fegan, C.
Davison, A.
Cartron, G.
Wright, J. G.
Saunders, A.
Honda, H.
Ono, T.
Sharpe, J.
Yoshizawa, T.
Yasuhiro, T.
Birkett, J.
BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 57 - 58
[28] Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies
Cheah, Chan Y.
Wickham, Nicholas
Yannakou, Costas K.
Lewis, Katharine L.
Hui, Chi-Hung
Tang, Pek Sang
Turpuseema, Tejasvi
Miskin, Hari P.
Tang, Jian-Ping
Normant, Emmanuel
Ricart, Alejandro D.
Tam, Constantine S.
BLOOD, 2019, 134
[29] A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies
Song, Yuqin
Sun, Mingyuan
Qi, Junyuan
Xu, Wei
Zhou, Jianfeng
Li, Dengju
Li, Jianyong
Qiu, Lugui
Du, Chenmu
Guo, Haiyi
Huang, Jane
Tang, Zhiyu
Ou, Ying
Wu, Binghao
Yu, Yiling
Zhu, Jun
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (01) : 62 - 72
[30] Clinical pharmacokinetics and pharmacodynamics of ME-401, an oral, potent and selective inhibitor of phosphatidylinositol 3-kinase P110δ, following single ascending dose administration to healthy volunteers
Moreno, Ofir
Imani, Robert
Zann, Vanessa
Leung, Pui
CANCER RESEARCH, 2016, 76

← 1 2 3 4 5 →